INSPRA
Generic Name for INSPRA
Eplerenone 25mg, 50mg; tabs.
Legal Classification:
Rx
Pharmacological Class for INSPRA
Aldosterone receptor blocker (mineralocorticoid-selective).
Manufacturer of INSPRA
Pfizer Labs
|
Indications for INSPRA
Hypertension.
Adult dose for INSPRA
Initially 50mg once daily; may increase after 4 weeks to max 50mg twice daily. Concomitant weak CYP3A4 inhibitors (eg, erythromycin, verapamil, saquinavir, fluconazole): initially 25mg once daily. Adjust based on serum K+ (see literature).
Children's dosing for INSPRA
Not recommended.
Contraindications for INSPRA
Hyperkalemia (serum K+ >5.5mEq/L) at initiation, severe renal impairment (CrCl ≤30mL/min), or concomitant potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, nelfinavir). Type 2 diabetes with microalbuminuria, CrCl<50mL/min, serum creatinine >2mg/dL (males), >1.8mg/dL (females), or concomitant K+ supplements or K+ sparing diuretics.
Warnings/Precautions for INSPRA
Severe hepatic impairment. Renal dysfunction. Monitor serum K+ at baseline, within 1st week, at 1 month after starting and after dose adjustment, then periodically. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
Interactions for INSPRA
CYP3A4 inhibitors (see Contraindications and Dose). NSAIDs may antagonize antihypertensive effects. Angiotensin II receptor blockers, ACEIs increase hyperkalemia risk. Monitor lithium.
Adverse Reactions for INSPRA
Hyperkalemia, dizziness, GI upset, abdominal pain, cough, flu-like symptoms, albuminuria; increased serum creatinine, triglycerides, cholesterol; decreased serum sodium; rare: sex hormone related effects, increased BUN, uric acid, liver enzymes.
How is INSPRA supplied?
Tabs—30, 90
Related Disease:
Hypertension